Authorized purpose: Estimate the presence and quantity of coronary artery calcium in patients aged 30 years and older from non-contrast ECG-gated chest CT, with informational segmentation and quantification available to a physician for adjunctive review.
Clinical role
On-demand adjunctive calcium categorization and quantification in the patient report or diagnostic image viewer, with the original report and cardiac CT remaining available for physician review.
Images and patients
CT/CTA · Coronary arteries and coronary artery calcium within the heart
Key limitation
Keep in mind: Use is limited to patients aged 30 years and older and non-contrast ECG-gated chest CT. Segmentation is informational only. Results are not for stand-alone use, do not replace the original report or scan, and must be interpreted by the physician before any patient action.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Estimate the presence and quantity of coronary artery calcium in patients aged 30 years and older from non-contrast ECG-gated chest CT, with informational segmentation and quantification available to a physician for adjunctive review.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Coronary arteries and coronary artery calcium within the heart Input: Non-contrast ECG-gated chest CT images in DICOM format from compatible CT systems; the comparison table identifies a default 130 HU calcium threshold.
Who uses it?Intended users: Interpreting physicians.
What does the software produce?Output: Four calcium-burden groups (0, 1-99, 100-399, and 400+ Agatston units), exact overall Agatston score, exact vessel-specific scores for LCA, LAD, LCX, and RCA, and a calcium segmentation over a copy of the original CT for informational purposes.
What is its most important limitation?Key limitation: Use is limited to patients aged 30 years and older and non-contrast ECG-gated chest CT. Segmentation is informational only. Results are not for stand-alone use, do not replace the original report or scan, and must be interpreted by the physician before any patient action.
Clinical takeaway. Clinical role: Estimate the presence and quantity of coronary artery calcium in patients aged 30 years and older from non-contrast ECG-gated chest CT, with informational segmentation and quantification available to a physician for adjunctive review.
Evidence takeaway. Evidence from the reviewed source record: FDA standalone retrospective pivotal testing used gated CT studies from six geographically diverse sites with representation from each calcium category. The primary endpoint was agreement between the four-category cardiovascular disease risk grouping and ground truth. Cohen weighted kappa was 0.972 (95% CI 0.958-0.987) against an acceptance criterion of at least 0.90. The reviewed FDA summary does not report the pivotal sample size.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Estimate the presence and quantity of coronary artery calcium in patients aged 30 years and older from non-contrast ECG-gated chest CT, with informational segmentation and quantification available to a physician for adjunctive review.
On-demand adjunctive calcium categorization and quantification in the patient report or diagnostic image viewer, with the original report and cardiac CT remaining available for physician review.
Four calcium-burden groups (0, 1-99, 100-399, and 400+ Agatston units), exact overall Agatston score, exact vessel-specific scores for LCA, LAD, LCX, and RCA, and a calcium segmentation over a copy of the original CT for informational purposes.
Medical-facility standard workflow for adults aged 30 years and older; the FDA comparison table identifies a medical facility but does not establish a specific deployment site.
Use is limited to patients aged 30 years and older and non-contrast ECG-gated chest CT. Segmentation is informational only. Results are not for stand-alone use, do not replace the original report or scan, and must be interpreted by the physician before any patient action.
FDA standalone retrospective pivotal testing used gated CT studies from six geographically diverse sites with representation from each calcium category. The primary endpoint was agreement between the four-category cardiovascular disease risk grouping and ground truth. Cohen weighted kappa was 0.972 (95% CI 0.958-0.987) against an acceptance criterion of at least 0.90. The reviewed FDA summary does not report the pivotal sample size.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA standalone retrospective pivotal testing used gated CT studies from six geographically diverse sites with representation from each calcium category. The primary endpoint was agreement between the four-category cardiovascular disease risk grouping and ground truth. Cohen weighted kappa was 0.972 (95% CI 0.958-0.987) against an acceptance criterion of at least 0.90. The reviewed FDA summary does not report the pivotal sample size.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
CAC (gated) Algorithm regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K240369
Sites6
IndependenceIndependence not established
K240369
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240369. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Non-contrast ECG-gated chest CT images in DICOM format from compatible CT systems; the comparison table identifies a default 130 HU calcium threshold.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Interfaces with compatible CT systems using DICOM; results can be made available on demand in a patient report or diagnostic image viewer, with optional DICOM Secondary Capture/report insertion described in the comparison. Specific PACS, RIS, EHR, and local interface compatibility are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Four calcium-burden groups (0, 1-99, 100-399, and 400+ Agatston units), exact overall Agatston score, exact vessel-specific scores for LCA, LAD, LCX, and RCA, and a calcium segmentation over a copy of the original CT for informational purposes.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Four calcium-burden groups (0, 1-99, 100-399, and 400+ Agatston units), exact overall Agatston score, exact vessel-specific scores for LCA, LAD, LCX, and RCA, and a calcium segmentation over a copy of the original CT for informational purposes.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Interfaces with compatible CT systems using DICOM; results can be made available on demand in a patient report or diagnostic image viewer, with optional DICOM Secondary Capture/report insertion described in the comparison. Specific PACS, RIS, EHR, and local interface compatibility are not established.
Bunkerhill Health's website states SOC 2 Type II certification, HIPAA compliance and ISO/IEC 27001:2022 certification. Badges only: no scope, dates or controls are given. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for CAC (gated) Algorithm; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K240369 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.